Patents by Inventor Lucas Hudson HOFMEISTER

Lucas Hudson HOFMEISTER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12098140
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    Type: Grant
    Filed: April 13, 2023
    Date of Patent: September 24, 2024
    Assignee: Bayer Aktiengesellschaft
    Inventors: Alexandros Vakalopoulos, Marie-Pierre Collin-Kröpelin, Nuria Ortega Hernandez, Andre Dieskau, Melissa Boultadakis-Arapinis, Lisa Candish, Timo Stellfeld, Ilka Mathar, Lucas Hudson Hofmeister, Peter Sandner, Frank Wunder, Lisa Dietz, Robert Alan Webster, Carsten Schmeck, Thomas Mondritzki
  • Publication number: 20240109864
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    Type: Application
    Filed: December 9, 2021
    Publication date: April 4, 2024
    Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK
  • Publication number: 20240101528
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    Type: Application
    Filed: December 9, 2021
    Publication date: March 28, 2024
    Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK
  • Publication number: 20240051935
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    Type: Application
    Filed: December 9, 2021
    Publication date: February 15, 2024
    Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK, Thomas MONDRITZKI
  • Publication number: 20230265072
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    Type: Application
    Filed: April 13, 2023
    Publication date: August 24, 2023
    Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK, Thomas MONDRITZKI
  • Publication number: 20220387608
    Abstract: The invention relates to stabilized Adrenomedullin derivatives and use thereof. In particular, the invention relates to novel, biologically active, stabilized Adrenomedullin (ADM) compounds. The invention further relates to the compounds for use in a method for the treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders, and to medicaments comprising the compounds for treatment and/or prevention of cardiovascular, edematous and/or inflammatory disorders.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 8, 2022
    Applicant: Bayer Aktiengesellschaft
    Inventors: Johannes KÖBBERLING, Donald BIERER, Ingo FLAMME, Bernd RIEDL, Lucas Hudson HOFMEISTER, Annette BECK-SICKINGER, Sylvia ELS-HEINDL, Jan-Patrick FISCHER, Eva-Maria JÜLKE
  • Publication number: 20220274958
    Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).
    Type: Application
    Filed: February 8, 2022
    Publication date: September 1, 2022
    Inventors: Alexandros VAKALOPOULOS, Marie-Pierre COLLIN-KRÖPELIN, Nuria ORTEGA HERNANDEZ, Andre DIESKAU, Melissa BOULTADAKIS-ARAPINIS, Lisa CANDISH, Timo STELLFELD, Ilka MATHAR, Lucas Hudson HOFMEISTER, Peter SANDNER, Frank WUNDER, Lisa DIETZ, Robert Alan WEBSTER, Carsten SCHMECK, Thomas MONDRITZKI
  • Publication number: 20210220357
    Abstract: The present invention relates to use 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds for the treatment or prophylaxis of diseases which are associated with nerve fiber sensitization, and/or other pathological conditions associated with autonomic imbalance caused by increased chemoreceptor sensitivity, in particular for the treatment of breathing disorders, Cheyne Stokes respiration, central and obstructive sleep apnea, cardiovascular disease, hypertension, resistant hypertension, and heart failure, which are related to increased activity of P2X3 receptors.
    Type: Application
    Filed: May 14, 2019
    Publication date: July 22, 2021
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Lucas Hudson HOFMEISTER, Oliver Martin FISCHER
  • Publication number: 20210139555
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 13, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Anke MAYER-BARTSCHMID, Damian BROCKSCHNIEDER, Marcel GEERTZ, Simone GREVEN, Lucas Hudson HOFMEISTER, Hannah JÖRISSEN, Christoph MAHLERT, Tobias MARQUARDT, Ilka MATHAR, Thomas MONDRITZKI, Claudia NOACK, Jan TEBBE, Stuart WALSH, Ernst WEBER, Andreas WILMEN, Frank WUNDER
  • Publication number: 20210079056
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a C-Type Natriuretic Peptide (CNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: March 18, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Damian BROCKSCHNIEDER, Lucas Hudson HOFMEISTER, Claudia NOACK, Jan TEBBE, Stuart WALSH, Andreas WILMEN, Frank WUNDER